PARIS & CAMBRIDGE, Mass. – NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanophysics-based approaches to expand treatment possibilities for patients with cancer, announced the publication of preclinical findings with the University of Texas MD Anderson Cancer Center (MD Anderson) in the...
Latest News
Kanazawa, Japan – Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have discovered how a protein called lamin A helps repair the protective barrier around a cell’s DNA. The findings reveal lamin A’s unique role and its potential for treating Hutchinson-Gilford Progeria Syndrome, a rare disorder that causes premature...
Champaign, Illinois – Neurodegenerative disorders such as Alzheimer’s disease affect more than 270 million people worldwide. AD is the leading cause of dementia, resulting in memory loss due to atrophy of neurons in the hippocampus, which is the part of the brain that regulates learning and memory. Nanoparticles designed to...
São Paulo, Brazil – A novel therapeutic strategy developed by researchers at São Paulo State University (UNESP) could revolutionize the treatment of visceral leishmaniasis, a neglected tropical disease (NTD) transmitted by sandflies. Some 12 million people suffer from the disease worldwide, and 700,000 to 1 million new cases of occur...
São Paulo, Brazil – A low-cost technology involving nanoparticles loaded with antibiotics and other antimicrobial compounds that can be used in multiple attacks on infections by the bacterium responsible for most cases of tuberculosis has been developed by researchers at São Paulo State University (UNESP) in Brazil and is reported...
DALLAS, TX — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy...
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has selected "sonpiretigene isteparvovec" for the nonproprietary name of the Company's MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP) and Stargardt disease.
DALLAS, Texas — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (FDA) and from the Scientific Advice meeting with the Icelandic Medicines Agency (IMA),...
Tokyo, Japan – Cancer has a high death rate with delayed diagnosis of the disease being one of the main reasons for its fatality. Early diagnosis of cancer is vital to improving patient outcomes and in recent years, the development of diagnostic tools to detect early-stage cancer has gained a...
SAN FRANCISCO, CA – Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company’s ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Members of Napo’s Scientific...